Javier Valencia

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

M. Hughes, R. Schooley, R. Gross, 2019, The lancet. HIV.

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

G. Bloomfield, M. Kozal, K. Tashima, 2020, The Journal of infectious diseases.

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

J. Kublin, N. Frahm, G. Pantaleo, 2019, Science Translational Medicine.

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial.

Michael T. Lu, P. Douglas, U. Lalloo, 2020, The Journal of infectious diseases.

One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis

R. Chaisson, S. Swindells, C. Fletcher, 2019, The New England journal of medicine.

Prevalence of Intimate Partner Violence, Substance Use Disorders and Depression among Incarcerated Women in Lima, Perú

P. Madhivanan, J. Lama, Joaquín Sánchez, 2021, International journal of environmental research and public health.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley, R. Gross, J. Mellors, 2022, Journal of the International AIDS Society.